secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prelude Therapeutics Inc (PRLD)
CIK:        0001678660
Form:       8-K
Filed at:   2026-04-21T23:59:59+00:00
Accession:  0001193125-26-164510
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prelude Therapeutics prices $90M public offering of common stock and pre-funded warrants
--------------------------------------------------------------------------------

- Offering of 18,018,014 common shares at $4.44/share and pre-funded warrants for 2,252,252 shares at $4.4399.
- Gross proceeds ~$90M; net proceeds ~$85.5M after expenses.
- Led by RA Capital Management and Soleus Capital; closes April 21, 2026.
- Proceeds to fund R&D, working capital; extends cash runway into Q2 2028.
- Underwriters: Goldman Sachs, Evercore ISI, Citizens Capital Markets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1678660/000119312526164510/0001193125-26-164510-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1678660/000119312526164510/d131537d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-164510

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer